Literature DB >> 6223223

Survival and PHA-stimulation of gamma-irradiated human peripheral blood T lymphocyte subpopulations.

J L Schwartz, J C Darr, M E Gaulden.   

Abstract

Human peripheral blood T lymphocyte subpopulations were identified and isolated on the basis of their ability to bind IgG (T-G), IgM (T-M), or neither immunoglobulin class (T-null). Lymphocytes were exposed to 0, 0.5, 1.0, 2.5 or 5.0 Gy of 60Co gamma-rays either as a T-cell suspension or as separated T cell subsets. Survival curves, determined 5 days after irradiation, revealed that each subset has radiosensitive and radioresistant portions, and that the T-G cell is the most sensitive subset. Mitotic indices of 48-h cultures showed that the response of unirradiated T lymphocytes to PHA varied greatly among the subsets, the highest indices being obtained for the T-M and the lowest for the T-G cells. With the possible exception of the T-G cells, the subsets are relatively resistant to mitotic effects of gamma-rays. T-G cells suppress the PHA-induced mitotic response of the other T lymphocyte subsets, and this suppressor effect is radiosensitive, being abolished by 1.0 Gy. It is concluded that lymphocytes exposed to greater than or equal to 1 Gy of gamma-rays will have very few dividing B lymphocytes or T-G cells. This together with radiation-induced loss of T-G suppressor action means that the predominant lymphocyte types in mitosis after greater than or equal to 1 Gy are the radioresistant T-M and T-null cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6223223     DOI: 10.1016/0027-5107(83)90180-x

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  2 in total

1.  Superinduction of the human gene encoding immune interferon.

Authors:  M A Lebendiker; C Tal; D Sayar; S Pilo; A Eilon; Y Banai; R Kaempfer
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

2.  Altered immune status of circulating T lymphocytes during sepsis: children also.

Authors:  Jean-Marc Cavaillon
Journal:  Crit Care       Date:  2014-08-14       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.